|
HEBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
3.774400E-04 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
5.038100E-03 |
| Stage1-vs-Stage3 |
6.203200E-01 |
| Stage1-vs-Stage4 |
2.10939999999438E-05 |
| Stage2-vs-Stage3 |
3.924700E-03 |
| Stage2-vs-Stage4 |
4.3247000000024E-06 |
| Stage3-vs-Stage4 |
3.539900E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
3.22829996068918E-09 |
| Normal-vs-Asian |
1.62447832963153E-12 |
| Caucasian-vs-AfricanAmerican |
3.328800E-01 |
| Caucasian-vs-Asian |
2.638000E-01 |
| AfricanAmerican-vs-Asian |
7.394400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
6.961400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.65867319878998E-12 |
| Normal-vs-Age(81-100Yrs) |
1.04249999743899E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.134200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.520170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.994800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.265200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.256200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.174200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.58049999999999E-05 |
| Classical-VS-Follicular |
4.22849999459629E-08 |
| Classical-VS-Other |
9.699000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.38542519070961E-12 |
| Tall-VS-Other |
2.521400E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
8.668500E-02 |
| Follicular-VS-Normal |
3.81050000000105E-05 |
| Other-VS-Normal |
6.73960000030505E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.80140038838783E-10 |
|
|
